Standard BioTools Inc. (LAB)
LAB trades on Nasdaq in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1162194/000119312526108326/0001193125-26-108326-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | LAB on Nasdaq |
| Sector | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Country | United States |
| IPO year | 2011 |
| SEC CIK | 0001162194 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $85.3M |
| Net income | -$74.9M |
| Operating income | -$110.2M |
| Net margin | -87.8% |
| Operating margin | -129.2% |
| Revenue growth | -6.2% |
| Cash | $120.9M |
| Total assets | $567.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $267.5M cash; operating cash flow -$16.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 394,790,441 (2026-11-01); 384,565,414 a year earlier; 79,395,035 three years earlier. | Cover page 2026-11-01 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-07-24 |
| Auditor | PricewaterhouseCoopers LLP, Irvine, California, United States | PCAOB Form AP 2026-03-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $14.4M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $19.4M | $13.5M | -$6.2M | $267.5M | $300K | $84.4M | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $20.1M | -$26.8M | -$10.3M | $270.0M | $299K | $84.6M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $21.1M | $127.1M | -$46.6M | $265.8M | $299K | $86.3M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $23.8M | $19.3M | -$1.2M | $120.9M | $299K | $85.3M | 10-K 2026-03-16 |
| Q3 2025 2025-09-30 | $19.6M | -$34.7M | -$22.2M | $129.4M | $299K | $86.3M | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $21.8M | -$33.5M | -$20.7M | $158.6M | $299K | $88.8M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $20.2M | -$26.0M | -$30.3M | $150.9M | $299K | $89.6M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $24.8M | -$34.1M | -$14.1M | $166.7M | $299K | $114.9M | 10-K 2026-03-16 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-10-30 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +10.9% |
| 1 month | +7.6% |
| 3 months | -5.3% |
| Year to date | -44.5% |
| 1 year | -40.8% |
| From 52-week high | -57.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Laboratory Analytical Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NAUT | Nautilus Biotechnology Inc. | $2.10 | -9.48% | $267.5M |
| QTRX | Quanterix Corporation | $2.84 | -3.07% | $134.8M |
| PACB | Pacific Biosciences of California Inc. | $1.84 | -6.12% | $575.8M |
| SEER | Seer Inc. | $1.48 | -5.73% | $82.6M |
| CTKB | Cytek Biosciences Inc. | $5.63 | -3.60% | $736.3M |
| HBIO | Harvard Bioscience Inc. | $8.91 | -5.96% | $40.7M |
| RPID | Rapid Micro Biosystems Inc. | $0.7400 | +13.67% | $37.1M |
| PRPO | Precipio Inc. | $19.96 | -9.81% | $35.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier